The hospital-acquired infection treatment market size was estimated to be worth USD 15.31 billion in 2023. The market is expected to rise at a growth rate of 4.2% in the forecast period of 2024-2032 to attain a market size of nearly USD 20.07 billion by 2032. Novel therapy launches and approvals are expected to fuel the market growth during the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hospital-acquired infection are infections that are acquired by the hospital or any other healthcare facility or from any healthcare professional, including doctors and nurses, among others, during the course of the treatment. The hospital-acquired infection are also referred to as healthcare-associated infections and nosocomial infections.
There are different types of healthcare-associated infections depending on the mode of entry of the causative pathogen and the type of the pathogen. According to the Centers for Disease Control and Prevention, nearly 1.7 million healthcare-associated infections were reported in the United States.
There are several modes of transmission attributing to the widespread of hospital-acquired infection, such as contact transmission, droplet transmission, airborne transmission, common vehicle transmission, and vector-borne transmission.
Nosocomial infections can be prevented by following several preventative steps and measures including sanitation, sterilisation, isolation, and frequent sanitation habits. The treatment for these types of infections is solely based on the eradication of the causative agents, responsible for causing the disease.
There are different antibiotics approved for eradicating or slowing the growth of the gram-positive strains of Staphylococcus aureus and gram-negative strains of Acinetobacter baumannii. Several other novel therapeutic medications are under clinical development for providing better therapeutic and diagnostic care.
According to the hospital-acquired infection treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Product and Services
Market Breakup by Infection Type
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growth of the hospital-acquired infection treatment market is primarily driven by the rising incidence and prevalence of healthcare-associated infections. This is further stimulated by the growing cases of chronic disorders and surgeries, which require prolonged hospital stays and thus will increase the risk of acquiring nosocomial infections. Additionally, the technological advancements in the devices implemented for infection control are also expected to bolster the market growth during the forecast period.
The hospital-acquired infection treatment market is augmented by the higher rate of surgical site infections, which is anticipated to increase the demand for the products and devices to manage hospital-acquired infection, and henceforth propel the market growth. According to the Centers for Disease Control and Prevention, nearly 20,000 surgical site infections were reported in the United States, thus accounting for significant market growth.
With extensive research and innovation, there is the discovery of novel therapeutic products by the key players and the major pharmaceutical companies. For example, Esco discovered a new sterilization device, incorporating a Cell Culture CO2 Incubator with High Heat Sterilization (CCL-HHS). The discovery of these devices will aid the eradication of the microorganisms contaminating the marketplace. Such product launches and approvals are expected to boost the market expansion in the forthcoming period.
Among the products segment, the disinfectants segment is anticipated to dominate the hospital-acquired infection treatment market owing to the increasing prevalence of chronic disorders, hospital-acquired infection, rising awareness, and the growing number of surgical interventions. Several reports suggested that nearly half of nosocomial infections occur in the intensive care units. The application of surface disinfectants aid in the prevention of these infections and will boost the market growth.
North America is anticipated to account for the largest share of the hospital-acquired infection treatment market due to the growth in hospital stays with the increase in the number of chronic diseases and surgeries. This can be attributed to the rising number of hospital admissions, that too for an extended period. Further, this will also increase the chances of hospital-acquired infection and will bolster the market development.
The hospital-acquired infection are generally treated with the help of medications and other home remedies. The diagnosis of the infection is performed using the help of blood tests, X-rays, and other diagnostic tests based on the symptoms.
Antibiotics are the most prescribed medications used for the treatment of nosocomial infections. The antibiotics act against the bacteria responsible for causing the infections by killing them or slowing their growth.
The two bacteria species that are likely to infect patients are Gram-positive strains of Staphylococcus aureus and Gram-negative strains of Acinetobacter baumannii. The frequent hospital-acquired infection are of the surgical site, urinary tract, and several types of pneumonia. An alternative treatment strategy used for the management of these infections is irradiation incorporating ultraviolet C.
In case the infection is caused by any foreign device such as a catheter, the doctor may remove it for the appropriate medical period. Home remedies such as the administration of a balanced diet, high fluid intake, and proper rest are the additional treatment measures that will assist in faster and better recovery.
With the increasing prevalence of chronic disorders, the risk of hospital-acquired infection also increases. For better diagnosis and treatment, clinical researchers and scientists are working on discovering novel therapeutic interventions that will aid in the management of non-cosmical infections.
Vir Biotechnology, a key market player, is evaluating the potential of its new therapies, VIR-3434 and VIR-2218, that could be considered as a functional cure for chronic hepatitis virus infection. This type of infection is categorised as healthcare-associated, and if successfully passed, it will help in bolstering the growth of the hospital-acquired infection treatment market.
Ascentage Pharma, another major pharmaceutical company, is performing clinical trials for the novel drug, which is anticipated to act by inhibiting the apoptosis protein antagonist in Chinese patients suffering from chronic hepatitis virus, which can be acquired from hospitals and other medical centres.
With time, the bacterial strains develop microbial resistance against the available antibiotics, thus the scientists are working on developing novel treatment options for managing resistant pneumonia. The newer treatment methods and faster approvals by the regulatory authorities are expected to boost the hospital-acquired infection treatment market growth during the forecast period.
The report gives an in-depth analysis of the key players involved in the hospital-acquired infection treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Products and Services||
|Breakup by Infection Type||
|Breakup by Application||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Hospital-Acquired Infection Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
18.104.22.168 Patent Status and Expiry
22.214.171.124 Timelines from Drug Development to Commercial Launch
126.96.36.199 New Drug Application
188.8.131.52.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
184.108.40.206 US FDA
220.127.116.11 EU EMA
18.104.22.168 INDIA CDSCO
22.214.171.124 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Hospital-Acquired Infection Treatment Market
8.1 Global Hospital-Acquired Infection Treatment Market Overview
8.2 Global Hospital-Acquired Infection Treatment Market Analysis
8.2.1 Market Overview
126.96.36.199 Global Hospital-Acquired Infection Treatment Market Historical Value (2017-2023)
188.8.131.52 Global Hospital-Acquired Infection Treatment Market Forecast Value (2024-2032)
8.2.2 Global Hospital-Acquired Infection Treatment Market by Products and Services
184.108.40.206 Market Overview
220.127.116.11.1.1 Sterilization Products
18.104.22.168.1.1.1 Heat Sterilization Equipment
22.214.171.124.1.1.2 Low-Temperature Sterilization Equipment
126.96.36.199.1.1.3 Radiation Sterilization Equipment
188.8.131.52.1.1.4 Other Sterilization Equipment
184.108.40.206.1.2 Contract Sterilization Services
220.127.116.11.1.3 Sterilization Consumables and Accessories
18.104.22.168.2 Cleaning and Disinfection Products
22.214.171.124.2.2 Disinfectors Equipment
126.96.36.199.3 Protective Barriers
188.8.131.52.4 Endoscope Reprocessing Products
8.2.3 Global Hospital-Acquired Infection Treatment Market by Infection Type
184.108.40.206 Market Overview
220.127.116.11.1 Hospital-acquired Pneumonia
18.104.22.168.2 Bloodstream Infections
22.214.171.124.3 Surgical Site Infections
126.96.36.199.4 Gastrointestinal Infections
188.8.131.52.5 Urinary Tract Infections (UTIs)
8.2.4 Global Hospital-Acquired Infection Treatment Market by Application
184.108.40.206 Market Overview
220.127.116.11.1 Drug-Resistance Testing
18.104.22.168.2 Disease Testing
8.2.5 Global Hospital-Acquired Infection Treatment Market by End User
22.214.171.124 Market Overview
126.96.36.199.1 Hospitals and ICUs
188.8.131.52.2 Ambulatory Surgical and Diagnostic Centres
184.108.40.206.3 Nursing Homes and Maternity Centres
8.2.6 Global Hospital-Acquired Infection Treatment Market by Region
220.127.116.11 Market Overview
18.104.22.168.1 North America
22.214.171.124.3 Asia Pacific
126.96.36.199.4 Middle East and Africa
188.8.131.52.5 Latin America
9 North America Hospital-Acquired Infection Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Hospital-Acquired Infection Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
11 Asia Pacific Hospital-Acquired Infection Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
12 Latin America Hospital-Acquired Infection Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
13 Middle East and Africa Hospital-Acquired Infection Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
14 Global Hospital-Acquired Infection Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Belimed AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Ecolab Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Getinge AB
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Bayer AG
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Novartis AG
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Merck & Co., Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Pfizer Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
16 Hospital-Acquired Infection Treatment Market- Drug Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customizable as per client requirements.
The market size is likely to reach a value of USD 15.31 billion in 2023.
The market is likely to grow at a CAGR of 4.2% during the forecast period of 2024-2032 to attain a value of USD 20.07 billion by 2032.
Based on the product and services, the market is segmented into sterilisation, cleaning and disinfection products, protective barriers, and endoscope reprocessing products.
Based on the infection type, the market is categorised into hospital-acquired Pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, and urinary tract infections, among others.
Based on the application, the market is segmented into drug-resistance testing and disease testing, among others.
Based on the end user, the market is categorised into hospitals and ICUs, ambulatory surgical and diagnostic centres, nursing homes and maternity centres.
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
The key companies involved in the market are 3M, Belimed AG, Ecolab Inc., Fortive, Getinge AB, Bayer AG, Danaher, Novartis AG, Merck & Co., Inc., Abbott, and Pfizer Inc., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.